The future of oncology research: Replacing case report forms with mCODE-aligned electronic health record data for clinical trial data curation (Alliance).

C Christopher Vetter (Dana-Farber Cancer Center, Boston, MA) A Amye Juliet Tevaarwerk (Mayo Clinic Rochester, Rochester, MN) N Nancy Campbell (Alliance Oncology, Boston, MA) H Hamid Emamekhoo S Selina Chow (Alliance for Clinical Trials in Oncology, Chicago, IL) C Cassandra Elrahi (Alliance, Alexandria, VA) W Winifred Commers (University of Wisconsin School of Medicine and Public Health, Madison, WI) A Alisha Birgin (Mayo Clinic Rochester, Rochester, MN) E Evanthia Galanis (Mayo Clinic, Rochester, MN) S Steven Piantadosi (Brigham and Women's Hospital, Boston, MA)

Abstract

e13661 Background: The process of data abstraction and curation represents a significant proportion of clinical trial costs, requiring up to $30,000 per patient depending on the data complexity. Research variables such as stage, performance status (PS), and cancer disease status are typically present in the electronic health record (EHR) in free text but require abstraction for research use. Structuring these real-world data (RWD) in an exportable format utilizing minimum common oncology data elements (mCODE) could reduce the need for abstraction and the potential for erroneous transcription that has been shown to be 5.51-7.72% in a meta-analysis. We assessed the feasibility, availability, and accuracy of RWD for use across Alliance for Clinical Trials in Oncology sites by comparing RWD to matched electronic case report form data (CRF data) at 2 sites where EHR-integrated tools collect structured RWD for all solid tumor patients. Methods: Stage, PS, and cancer disease status (CDS) were extracted from the EHR as RWD and from eCRFs for 100 patients enrolled in National Clinical Trials Network trials across multiple disease sites from 2022 through 2025. Data from baseline and day 1 of cycles 1-4 were compared (500 encounter timepoints). Results: Stage, PS, and CDS were available from RWD more often than CRFs (85 vs 70 / 100 patients, 436 vs 416 / 500 encounters, and 345 vs 83 / 500 encounters respectively). When stage was present in both (n = 58), there were 5 mismatches (8.6%). PS had 22 mismatches (4%) and CDS had 45 mismatches (11.4%). After correcting for differences in CRF vs RWD definitions, CDS mismatches dropped to 1.2% (n = 4). Discordance between RWD and CRF data was related to differences in the timepoint of data collection (e.g., systemic staging scans completed after the initial consult), CRF data obtained from other EHR notes (e.g., oncology research nurse notes containing PS), inherent discordance between RWD and CRF data choices (e.g., responding vs complete or partial response), and failure to update EHR data capture tool fields. RWD were available 21 days (median) before CRF data. Conclusions: Our results suggest that RWD captured directly within clinical notes match CRF data, are more often present, and are available sooner. RWD could serve as a data source for trials, decreasing the need for manual curation and cost. Although some discordance exists, overall rates are low and close to the published error rate for abstraction.

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (10)

C

Christopher Vetter

Dana-Farber Cancer Center, Boston, MA

A

Amye Juliet Tevaarwerk

Mayo Clinic Rochester, Rochester, MN

N

Nancy Campbell

Alliance Oncology, Boston, MA

H

Hamid Emamekhoo

S

Selina Chow

Alliance for Clinical Trials in Oncology, Chicago, IL

C

Cassandra Elrahi

Alliance, Alexandria, VA

W

Winifred Commers

University of Wisconsin School of Medicine and Public Health, Madison, WI

A

Alisha Birgin

Mayo Clinic Rochester, Rochester, MN

E

Evanthia Galanis

Mayo Clinic, Rochester, MN

S

Steven Piantadosi

Brigham and Women's Hospital, Boston, MA